Abstract Immune-mediated uveitis is a collective term referring to a group of potentially blinding intraocular inflammations which may coexist with systemic inflammatory diseases. T lymphocytes appear to play an important pathogenic role in uveitis, and these cells are therefore the logical target of drug therapy. Corticosteroids act nonspecifically, but are highly effective in controlling the inflammation rapidly. They are administered locally when disease is confined to the anterior portion of the eye. However, posterior eye involvement often requires systemic corticosteroid therapy, carrying a high risk of serious adverse effects when used for extended periods. In this situation, steroid-sparing agents are used. Few relevant randomised, controlled clinical trials have been performed, and the choice of systemic immunosuppressive regimen is usually guided by individual patient characteristics, cost, drug availability and physician preference. Patients should actively participate in therapeutic decision-making. Our first choice for steroid-sparing medication is often methotrexate, an anti-metabolite which carries a low risk of adverse reactions when appropriately prescribed and monitored, is relatively inexpensive, and has once-weekly ease of use. For more severe uveitis, we may combine the immunomodulating agent cyclosporin with methotrexate and a corticosteroid. Azathioprine and cyclophosphamide are other treatment options. Steroid-sparing drugs also have significant potential for causing adverse effects, albeit less frequently than corticosteroids. Future therapies aim to reduce this problem by increasing the specificity of the therapeutic action.
immunosuppressive   0.8227032485120301^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Immunosuppression     

adverse effects               0.999999997738314^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Adverse_effect        

disease                       0.9999999844683317^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Infection             

corticosteroid                1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Corticosteroid        

physician                     0.9999946032221595^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Health_care_provider  

eye                           0.9999999999809006^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Human_eye             

drug therapy                  0.9995284444336944^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Pharmaceutical_drug   

Azathioprine                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Azathioprine          

drug                          0.9999991141455042^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Pharmaceutical_drug   

inflammations                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Inflammation          

uveitis                       1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Uveitis               

inflammation                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Inflammation          

cyclosporin                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ciclosporin           

Immune-mediated               1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Immune_disorder       

cells                         0.9999999999961346^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Cell_(biology)        

uveitis                       1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Uveitis               

methotrexate                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Methotrexate          

Corticosteroids               1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Corticosteroid        

medication                    0.9999999966059931^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Pharmaceutical_drug   

corticosteroids               1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Corticosteroid        

anterior                      0.5937836552396734^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Anterior_pituitary    

cyclophosphamide              1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Cyclophosphamide      

drugs                         0.9999989475760311^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Pharmaceutical_drug   

corticosteroid                1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Corticosteroid        

pathogenic                    0.9999999868002761^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Pathogen              

methotrexate                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Methotrexate          

uveitis                       1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Uveitis               

posterior                     0.8822597532195908^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Anatomical_terms_of_location

T lymphocytes                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/T_cell                

specificity                   0.999988161641838^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Sensitivity_and_specificity

adverse effects               0.999999997738314^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Adverse_effect        

inflammatory diseases         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Inflammation          

immunomodulating              1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Immunotherapy         

eye                           0.9999999999809006^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Human_eye             

controlled clinical trials    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Clinical_trial        

adverse reactions             0.9999999947181095^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Adverse_effect        

